The investigational new drug (IND) application contains which of the following information? A. Toxicity of the test drug in humans B. Effectiveness of the test drug in humans C. Toxicity of the test drug in animals D. Safety and effectiveness of the test drug after FDA approval

Question

ToriBaybee ToriBaybee

21-08-2016
Health

contestada

The investigational new drug (IND) application contains which of the following information? A. Toxicity of the test drug in humans B. Effectiveness of the test drug in humans C. Toxicity of the test drug in animals D. Safety and effectiveness of the test drug after FDA approval

Respuesta :

Otras preguntas

3. How did the views of Native Americans and Europeans differ in terms of property ownership?

Neeta bought 2 and 3/5 liter of milk from the market.To make it 3 liters, how much more does she need?

Which United States president secured a détente with both China and the Soviet Union, ended U.S. involvement in Vietnam, and resigned after the Watergate scanda

people in sahel usually work in secondary industry wheres the mistake

given V=4/3(pi)r^(3) and S=4(pi)r^(2) for a sphere, and the fact that the radius of the sphere is decreasing at 1/2 inches per minute, find the rate at which th

How does the absorption and release of energy affect temperature change during a chemical reaction?

The weight of Jacob’s backpack is made up of the weight of the contents of the backpack as well as the weight of the backpack itself. Seventy percent of the tot

20. First and foremost, supervisors are A. Leaders B.Teachers C.Counselor D. Advocates

Which article of the United States Constitution outlines the structure and powers of the executive branch?

Simplify 0.5×(4a+6b) using the disturbtive property.

Kylercarter199 Kylercarter199 · Answer 1 · 2017-12-04T19:00:02+01:00

Accelerated development/review (Federal Register, April 15, 1992) is a highly specialized mechanism for speeding the development of drugs that promise significant benefit over existing therapy for serious or life-threatening illnesses for which no therapy exists. This process incorporates several novel elements aimed at making sure that rapid development and review is balanced by safeguards to protect both the patients and the integrity of the regulatory process.